AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Switglim MV 2/0.3 Tablet ER

Prescription Icon
Prescription Required

Marketer

Akumentis Healthcare Ltd

Salt Composition

Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)

Overview Switglim MV 2/0.3 Tablet ER

Diabetics using Glyciphage Duo ER (a dual-action antidiabetic medication) manage type 2 diabetes mellitus. This combined formulation regulates blood glucose in adults. Administer Glyciphage Duo ER with meals, consistently at the same time daily for optimal efficacy. Dosage is personalized and may adjust based on blood sugar monitoring. Continuous use, even with controlled glucose levels, is crucial. Discontinuing without medical guidance risks elevated blood sugar, potentially causing kidney damage, vision impairment, neuropathy, and limb loss. This medicine complements a comprehensive diabetes management plan, including diet, exercise, and weight management as directed by your physician. Lifestyle significantly impacts diabetes control. Hypoglycemia (low blood sugar) is a prevalent side effect, characterized by sweating, dizziness, headache, and tremors. Maintain regular meals and carry fast-acting glucose sources (e.g., sugary foods, fruit juice) to mitigate this risk. Alcohol consumption elevates hypoglycemia risk and should be avoided. Additional potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. Glyciphage Duo ER is contraindicated for type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should consult their physician before initiating treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring is essential, along with periodic blood tests to assess blood cell counts and liver function.

Primary Ingredients of Switglim MV 2/0.3 Tablet ER

No information provided. Please provide the text you wish me to rephrase.

Uses of Switglim MV 2/0.3 Tablet ER

Managing type 2 diabetes

Major Benefits of Switglim MV 2/0.3 Tablet ER:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Switglim MV 2/0.3 Tablet ER should be taken on an empty stomach.

Common Side effects of Switglim MV 2/0.3 Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Switglim MV 2/0.3 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Switglim MV 2/0.3 Tablet ER should be taken on an empty stomach.

How Switglim MV 2/0.3 Tablet ER works:

Extended-release Switglim MV tablets (2mg/0.3mg) contain a triple-action antidiabetic formulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Switglim MV 2/0.3 Tablet ER and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Switglim MV 2/0.3 Tablet ER during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential benefits against any risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Switglim MV 2/0.3 mg tablets are likely unsuitable for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyUNSAFE

Employing Switglim MV 2/0.3 Tablet ER carries a high likelihood of risk for individuals with kidney impairment and should be strictly avoided. Medical advice is essential. Furthermore, this medication is unsuitable for patients exhibiting severe kidney dysfunction.

LiverLiverCAUTION

Exercise caution when prescribing Switglim MV 2/0.3 Tablet ER to individuals with hepatic impairment; dosage modifications may be necessary. Consult a physician before administering. For patients exhibiting mild to moderate liver disease, initiate treatment with a reduced Switglim MV 2/0.3 Tablet ER dose; avoid use in those with severe hepatic dysfunction.

What if you forget to take Switglim MV 2/0.3 Tablet ER :

Should you forget to take a Switglim MV 2/0.3 Tablet ER, administer it immediately upon remembrance. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Switglim MV 2/0.3 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Switglim MV 2/0.3 Tablet ER

Switglim MV 2/0.3 Tablet ER combines glimepiride, metformin, and voglibose to manage type 2 diabetes mellitus in adults. This triple-drug therapy, used alongside diet and exercise, improves blood glucose control. Glimepiride stimulates insulin release; metformin reduces liver glucose production and enhances insulin sensitivity; and voglibose, an alpha-glucosidase inhibitor, lowers postprandial glucose. This combination is unsuitable for type 1 diabetes.
Switglim MV 2/0.3 Tablet ER may cause common side effects including hypoglycemia, nausea, diarrhea, altered taste, flatulence, abdominal pain, headache, rash, and respiratory infection.
Switglim MV 2/0.3 Tablet ER is contraindicated in patients with allergies to its components or excipients, those with moderate to severe kidney disease, and those with inflammatory bowel disease, colonic ulcerations, or underlying metabolic acidosis, including diabetic ketoacidosis.
Combining Switglim MV 2/0.3 Tablet ER and alcohol is unsafe. This combination can dangerously lower blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Switglim MV 2/0.3 Tablet ER can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice to treat low blood sugar.
Store this medication, tightly sealed, in its original packaging. Follow the storage instructions on the package or label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Switglim MV 2/0.3 Tablet ...
127
MRP 147
13% off